Biotechnology
CNS Pharmaceuticals Inc. to Showcase Innovative Cancer Treatments at Webull Financial Biotech/MedTech Webinar
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) will present its groundbreaking cancer treatment research at the upcoming Webull Financial Corporate Connect Webinar Series, highlighting the potential of its drug candidate TPI 287 in treating brain and central nervous system cancers.
Soligenix Inc. Reports Q2 2025 Results with Progress in Rare Disease Treatments
Soligenix Inc. highlights advancements in its rare disease treatment pipeline, including progress in psoriasis and cutaneous T-cell lymphoma therapies, amidst a widened net loss in Q2 2025.
Clene Inc. Advances Toward FDA Submission for ALS Therapy with Promising Q2 2025 Results
Clene Inc. reports significant progress in its Q2 2025 results, targeting a year-end NDA submission for its ALS therapy, CNM-Au8, with sufficient cash runway into Q1 2026.
Intensity Therapeutics Pioneers New Cancer Treatment with Minimal Side Effects
Intensity Therapeutics is advancing a novel cancer treatment that directly targets tumors with minimal side effects, offering hope for patients with refractory solid tumors.
Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns
Soligenix Inc. is progressing with RiVax®, a heat-stable vaccine against ricin toxin, showcasing significant potential in biodefense and public safety.
AAA Biotech Expands Recombinant Proteins Portfolio to Advance Life Sciences Research
AAA Biotech enhances its recombinant proteins portfolio, offering high-quality research reagents to support groundbreaking biomedical research.
Calidi Biotherapeutics Inc. Reports Q2 2025 Financial Results and Advances in Oncology Research
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has reported its Q2 2025 financial results, showcasing a reduced net loss and significant progress in its oncology research, including FDA Fast Track Designation for its CLD-201 treatment in soft tissue sarcoma.
Alliance Global Partners Raises Soligenix Inc. Price Target Amid Clinical Progress
Alliance Global Partners has increased Soligenix Inc.'s price target to $10 per share, citing advancements in its clinical programs for rare diseases.
Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS
Quantum BioPharma Ltd. has taken a significant step towards clinical trials for its oral Lucid-MS treatment for multiple sclerosis by partnering with a leading contract development and manufacturing organization.
Breakthrough Lung Cancer Treatment Enhances Chemotherapy with Mitochondrial Transplantation
Researchers in China have developed a novel lung cancer treatment that combines chemotherapy with mitochondrial transplantation to significantly improve treatment efficacy and immune response.
Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
Lantern Pharma Inc. has successfully completed patient enrollment in Japan for its Phase 2 HARMONIC(TM) trial targeting never-smoker non-small cell lung cancer patients, a significant step towards addressing a critical unmet medical need.
GeoVax Advocates for MVA-Based Vaccines Following HHS mRNA Vaccine Rollback
GeoVax Labs highlights the advantages of its MVA-based multi-antigen vaccine, GEO-CM04S1, as a solution to the limitations of mRNA vaccines identified by the HHS, emphasizing broader and more durable protection against COVID-19 and other viruses.
Aditxt Inc. Portfolio Company CEO Recognized for Advancements in Women's Health
Saundra Pelletier, CEO of Evofem Biosciences, a pending acquisition target of Aditxt Inc., has been awarded the Trailblazing Female Founders Award for her contributions to women's sexual and reproductive health, highlighting the significance of Aditxt's upcoming acquisition in expanding its focus on women's health.
EnPlusOne Biosciences Aims to Revolutionize RNA Therapeutics with Enzymatic Synthesis
EnPlusOne Biosciences, under the leadership of CEO Clare Murray Ph.D., is pioneering an enzymatic approach to RNA synthesis, addressing the limitations of current methods and paving the way for scalable, pure, and environmentally friendly RNA therapeutics.
Lantern Pharma Introduces AI Tool PredictBBB.ai(TM) with 94% Accuracy in Predicting Blood-Brain Barrier Permeability
Lantern Pharma's new AI module, predictBBB.ai(TM), significantly enhances the prediction of small molecules' ability to cross the blood-brain barrier, addressing a major challenge in drug development.
Intensity Therapeutics Secures $6.6 Million to Advance Cancer Treatment Research
Intensity Therapeutics raises $6.6 million through an At-the-Market offering to fund clinical trials for its innovative cancer therapy, INT230-6, marking a significant step forward in the fight against cancer.
Intensity Therapeutics Raises $6.6 Million in July 2025 Through At-The-Market Stock Sales
Intensity Therapeutics, Inc. bolstered its financial position by securing $6.6 million through at-the-market stock sales, enabling further advancement of its innovative cancer therapy clinical trials.
Genetic Breakthrough Could Personalize Brain Tumor Treatment
Researchers at the University of Kentucky have discovered a genetic biomarker that could help predict which glioblastoma patients may benefit from the drug bevacizumab, offering a new avenue for personalized cancer treatment.
D. Boral Capital LLC Facilitates $22 Million Offering for Omeros Corporation
D. Boral Capital LLC's role as the exclusive placement agent in Omeros Corporation's $22 million registered direct offering highlights the firm's pivotal position in facilitating significant financial transactions for emerging growth companies.
BIO 2025 Trend Report Highlights Biotech's Shift Towards Scalability and Human-Centric Innovation
The BIO 2025 Pulse of the Industry Report by Norvell Jefferson underscores the biotech sector's evolution towards scalable, meaningful innovations that prioritize human-centric approaches and strategic branding.
Lantern Pharma Achieves Milestone in Phase 2 HARMONIC Trial for Non-Smoker NSCLC Patients in Japan
Lantern Pharma completes targeted enrollment for its Phase 2 HARMONIC trial in Japan, marking a significant step in its international expansion and offering hope for never-smoker NSCLC patients.
NanoCell Therapeutics' NCtx Platform Could Revolutionize CAR-T Therapy Accessibility
NanoCell Therapeutics' research demonstrates a novel method for in vivo CAR-T cell generation, potentially reducing costs and increasing access to life-saving cancer treatments.
Creative Biolabs Advances Single-Domain Antibody Solutions to Meet Therapeutic Demands
Creative Biolabs is enhancing the development of single-domain antibodies (sdAbs), offering innovative solutions for oncology, neurology, and infectious diseases, highlighting their potential to revolutionize treatment approaches.
Creative Biolabs to Showcase Tumoroid-on-a-Chip Technology in Upcoming Webinar
Creative Biolabs is set to host a webinar on tumoroid-on-a-chip technology, highlighting its potential to revolutionize cancer research and drug development by offering more physiologically relevant conditions for preclinical testing.
Xtant Medical Collaborates with B2i Digital to Highlight Orthobiologics Innovation to Investors
Xtant Medical's partnership with B2i Digital aims to educate investors on its orthobiologics platform and market potential, showcasing its growth in the medical technology sector.
GeoVax Advances in Vaccine Development and Immunotherapy with Promising Clinical Data
GeoVax Labs reports significant progress in its vaccine and immunotherapy pipeline, including favorable regulatory guidance for GEO-MVA and robust immune responses from GEO-CM04S1 in CLL patients, highlighting the company's potential to address urgent medical needs.
Lantern Pharma Strengthens Board with Appointment of Dr. Lee T. Schalop to Advance AI-Driven Oncology Research
Lantern Pharma enhances its AI-driven precision oncology efforts by appointing Dr. Lee T. Schalop, a seasoned biotech leader, to its Board of Directors.
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Optimize Market Dynamics
Calidi Biotherapeutics Inc. (NYSE American: CLDI) will implement a 1-for-12 reverse stock split effective August 5, 2025, aiming to enhance market appeal and align with shareholder interests.
Fifty 1 Labs and UAV Corp to Host Virtual Shareholder Teleconference with Nobel Laureate Dr. James Orbinski
Fifty 1 Labs and UAV Corp announce a virtual shareholder teleconference featuring Nobel Laureate Dr. James Orbinski, highlighting strategic initiatives in AI-driven health solutions and biotech acquisitions.
GeoVax Explores Needle-Free Vaccine Delivery with Vaxxas Technology
GeoVax Labs, Inc. initiates a research program to evaluate the potential of a needle-free, self-administered GEO-MVA vaccine using Vaxxas' HD-MAP technology, aiming to enhance global immunization efforts.